Start-up raises $173 million to develop gene-therapy-alternative infusion for sickle cell disease
A new biotechnology company has secured substantial funding to pursue a sickle cell treatment designed to match gene therapy efficacy without the manufacturing and delivery complexities associated with current gene-based approaches.
STAT News reports that a new start-up has raised $173 million to develop an infusion-based treatment for sickle cell disease that its founders say could achieve outcomes comparable to gene therapy, without the drawbacks — including the high cost, lengthy manufacturing time, and conditioning regimens currently required for gene therapy approaches.
Sickle cell disease affects millions of people worldwide and is caused by a well-characterised mutation in the β-globin gene. While gene therapies for SCD have received regulatory approval in recent years, their real-world uptake has been limited by logistical and cost barriers. The start-up's approach, described in STAT News but not yet in peer-reviewed literature, is positioned as a simpler alternative delivery modality.
The report does not provide detailed mechanistic information about the treatment or preclinical data. As a funding announcement, it reflects investor and founder confidence in a research hypothesis rather than documented clinical efficacy. Researchers and those tracking the sickle cell therapeutic landscape may note it as a signal of continued interest in non-gene-therapy modalities for haemoglobinopathies.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary source Stat News · 2026-11-17STAT+: With $173 million, new startup takes aim at sickle cell